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Hepatitis C virus (HCV) belongs to
the Flaviviridae family, and its genome
is a single-stranded RNA molecule
(genomic HCV-RNA).1 Virus replica-
tion involves the synthesis of a comple-
mentary RNA (antigenomic HCV-
RNA) that acts as a template for
production of genomic HCV-RNA.2
Despite screening of blood products
for anti-HCV and implementation of
precaution measures, HCV infection is
still a major problem in hemodialysis
(HD) units.3,4 Routine serologic con-
trols performed biannually (including
qualitative PCR technology) and test-
ing at least every 2 mo for alanine ami-
notransferase (ALT) and -glutamyl
transpeptidase (-GTP) levels are im-
portant for monitoring viral hepatitis
transmission within HD units.5,6 When
ALT values are 28 IU/L (upper nor-
mal limit for hemodialysis patients)7–9
and/or -GTP levels are increased
(43 IU/L), viral markers (hepatitis B
surface antigen and DNA, anti-HCV,
and HCV-RNA) and nonviral causes of
liver disease (e.g., autoimmunity, toxic
hepatitis, metabolic disorders) are
studied to identify the cause of the ele-
vated liver enzymes; however, the
cause of liver disease cannot be estab-
lished in approximately 2% of HD pa-
tients (personal observation).
It was reported that up to 57% of pa-
tients with normal renal function but
with abnormal values of liver enzymes of
unknown cause have an occult HCV in-
fection (presence of HCV- RNA in liver
in absence of anti-HCV and serum
HCV-RNA).10 Furthermore, 70% of
these patients also have HCV-RNA in
peripheral blood mononuclear cells
(PBMC). Thus, although detection of
HCV genome in liver is the most accu-
rate method for the diagnosis of occult
HCV in all patients, testing for HCV-
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ABSTRACT
Occult hepatitis C virus (HCV) infection (i.e., detectable HCV-RNA in the liver or
peripheral blood mononuclear cells) in the absence of both serum HCV-RNA and
anti-HCV antibodies has not been investigated in hemodialysis patients. In this
study, real-time PCR and in situ hybridization was used to test for the presence
of genomic and antigenomic HCV-RNA in peripheral blood mononuclear cells of
109 hemodialysis patients with abnormal levels of liver enzymes. Occult HCV
infection, determined by the presence of genomic HCV-RNA, was found in 45%
of the patients; 53% of these patients had ongoing HCV replication, indicated by
the presence of antigenomic HCV-RNA. Patients with occult HCV infection had
spent a significantly longer time on hemodialysis and had significantly higher
mean alanine aminotransferase levels during the 6 mo before study entry. Lo-
gistic regression analysis revealed that mortality was associated with age 60 yr
(odds ratio 3.30; 95% confidence interval 1.05 to 10.33) and the presence of
occult HCV infection (odds ratio 3.84; 95% confidence interval 1.29 to 11.43). In
conclusion, the prevalence of occult HCV infection is high among hemodialysis
patients with persistently abnormal values of liver enzymes of unknown cause. The
clinical significance of occult HCV infection in these patients requires further study.
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RNA in PBMC is an alternative proce-
dure when a liver biopsy is not available.
Until now, the presence of occult
HCV infection in HD units has not been
studied. This work aimed to (1) study the
existence of occult HCV infection by
testing for genomicHCV-RNA in PBMC
of hemodialysis patients with abnormal
levels of liver function tests of unknown
cause and (2) determine whether the vi-
rus was replicating in these cells by de-
tecting the antigenomic HCV-RNA.
A total of 109 HD patients (71 men, 38
women) who were repeatedly anti-HCV
and serum HCV-RNA negative and had
abnormal liver function tests of unknown
cause for 23.8 24.5 mo were included in
the study. Their mean age was 61.7 14.9
yr. The mean duration on maintenance
HDwas 51.5 49.7mo, and 59 (54%) pa-
tients had received blood transfusions. On
study entry, mean ALT and -GTP levels
were, respectively, 34.1 21.2 and 99.3
82.0 IU/L, whereas during the 6mo before
the beginning of the study, mean ALT was
25.7  15.1 IU/L and mean -GTP was
80.0 69.5 IU/L.
Genomic HCV-RNA was found by
strand-specific real-time PCR in PBMC
of 49 (45%) of 109 patients, indicating
that they had an occult HCV infection.
Viral RNA was not detected in negative
controls, and the results of HCV-RNA
detection performed by different opera-
tors on different days were identical in all
cases. Mean load SEM of the genomic
HCV-RNA was 6.6  104 7.8  103
copies of HCV-RNA per g of total
RNA. Presence or absence of genomic
HCV-RNA was confirmed by fluores-
cence in situ hybridization.
Genotyping of the HCV-RNA iso-
lated from PBMC showed that the 49
positive patients had HCV genotype 1.
Sequence analysis of the HCV core re-
gion from six randomly selected cases
confirmed thatHCV isolates belonged to
genotype 1b. Phylogenetic analysis dem-
onstrated that the genetic distances of the
clones within patients were lower than
among patients (Table 1), except in pa-
tient 5 because one of his clones segre-
gated separately fromtheothers (Figure1).
The phylogenetic tree showed that the
clones segregated separately in the six pa-
tients, indicating that no cross-contamina-
tion among samples occurred (Figure 1).
RegardingHCV replication in PBMC,
antigenomic HCV-RNA was found by
strand-specific real-time PCR in 26
(53%) of 49 patients with occult HCV
(mean load SEM of 7.3 103 1.2
103 copies perg of total RNA). This on-
going viral replication was confirmed by
fluorescence in situ hybridization.
No differences were found in demo-
graphic or clinical features between pa-
tients with and without occult HCV in-
fection on study entry, except that the
occult HCV infection group showed a
longer duration of hemodialysis (63.9
62.1 versus 41.4  34.1 mo; P  0.03).
During the 6 mo before inclusion into
the study, themeanALT level (four to six
values per patient) was significantly
higher (P 0.04) in patients with occult
HCV infection (29.0  15.5 IU/L) than
in the negative ones (23.1  14.4 IU/L),
but no difference was found in the mean
-GTP level. Within the group of occult
HCV infection, patients with presence of
replicating virus (as detected by antige-
nomic HCV-RNA) did not differ in any
demographic or laboratory features from
those without replication.
After entry into the study, patients
with and without occult HCV infection
were followed for 12.9  14.4 and
15.8  15.1 mo, respectively. All re-
mained anti-HCV and serum HCV-
RNA negative with abnormal ALT
and/or -GTP values. In occult HCV
infection, 39% (19 of 45) of the pa-
tients died during the follow-up pe-
riod, a percentage significantly higher
than that of patients without occult
HCV (12 [20%] of 60; P  0.031). In a
binary logistic regression analysis, it
was found that mortality was associ-
ated with age 60 yr (odds ratio [OR]
3.30; 95% confidence interval [CI] 1.05
to 10.33; P  0.04) and with the pres-
ence of occult HCV infection (OR 3.84;
95% CI 1.29 to 11.43; P 0.015). None
of the deaths was attributed to liver dis-
ease, but deceased patients with occult
HCV infection had significantly higher
ALT levels than those without occult
HCV (26.8  14.0 versus 16.7  8.0
IU/L; P 0.032). In addition, deceased
patients with occult HCV infection
were significantly younger than the
negative ones (61.4  14.6 versus
74.1 3.3 yr; P 0.002). Among alive
patients, 11 (seven patients with and
four without occult HCV infection) re-
ceived a kidney transplant; the remain-
ing patients continued on HD. Within
the group of occult HCV, no differ-
ences were found between patients
with viral replication in PBMC and
those without it. One of the patients
with occult HCV, who was placed on
the renal transplantation waiting list,
underwent a liver biopsy for histologic
assessment and to confirm occult HCV
infection. By strand-specific real-time
PCR and by in situ hybridization, it was
demonstrated that HCV was infecting
and replicating in the liver cells. Liver
histology revealed cholestasis, but
necroinflammation or fibrosis was not
Table 1. Mean genetic distances (SE) between the sequences within a patient and among patients
Patient
Patient
1 2 3 4 5 6
1 0.005 (0.003) 0.014 (0.006) 0.018 (0.007) 0.023 (0.008) 0.022 (0.005) 0.026 (0.008)
2 0.007 (0.004) 0.020 (0.007) 0.024 (0.008) 0.024 (0.006) 0.027 (0.008)
3 0.002 (0.002) 0.024 (0.009) 0.025 (0.007) 0.027 (0.009)
4 0.007 (0.003) 0.028 (0.007) 0.026 (0.008)
5 0.024 (0.006) 0.031 (0.007)
6 0.006 (0.003)
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detected. In another patient with oc-
cult HCV, liver cirrhosis was visualized
during a laparoscopy procedure.
Patients who have normal renal
function but abnormal liver function
tests and are anti-HCV and serum
HCV-RNA negative may have an oc-
cult HCV infection in liver and in
PBMC.10 In this work, we detected the
Figure 1. Neighbor-Joining tree constructed
with the HCV core nucleotide sequences of
the clones of the six randomly selected pa-
tients and those corresponding to the various
HCV genotypes. Bootstrap values 70, ob-
tained after 1000 replicates of the data sheet,
are shown in the nodes of the tree.
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presence of the genomic HCV-RNA in
PBMC of a high percentage (45%) of
anti-HCV– and serum HCV-RNA–
negative HD patients with abnormal
ALT and/or -GTP values, indicating
that they have an occult HCV infection.
Furthermore, antigenomic HCV-RNA
was detected in 53%of theseHDpatients
with occult HCV, showing that HCV is
replicating in PBMC and suggesting that
these patients could be potentially infec-
tious; therefore, because universal pre-
cautions may not be strictly followed
when patients present abnormal liver
function tests of unknown cause, occult
HCV infection could play a role in HCV
spread within HD units.
According to the original report of oc-
cult HCV infection,10 all HD patients
withHCV-RNA inPBMCmust also have
viral RNA in liver. This could be verified
in the patient who had occultHCV infec-
tion and underwent a liver biopsy. Nev-
ertheless, it should be stressed that detec-
tion of HCV-RNA in PBMC does not
identify all cases with occult HCV, so
some of the HD patients without viral
RNA in PBMC could have an occult
HCV infection in liver; however, liver bi-
opsy is not routinely recommended for
HD patients except in a subset of cases
(e.g., in renal transplant candidates, be-
fore starting antiviral therapy).
Duration of HD was significantly
longer in patientswith occultHCV infec-
tion, whereas antecedents of blood trans-
fusion did not differ between groups.
This finding suggests the possible role of
nosocomial transmission in the spread of
occult HCV, as reported in HD units for
“classical” HCV infection.1,2,11
During the follow-up study, it was
found thatmortality was significantly as-
sociated with age and with the presence
of occult HCV infection. None of the
deaths could be attributed to liver dis-
ease; however, that deceased patients
with occult HCVhad significantly higher
ALT levels than deceased uninfected pa-
tients and the finding of liver cirrhosis in
one of the two patients who had occult
HCV infection and for whom liver his-
tology was available suggest that occult
HCV infection may contribute to the
worse outcome of these patients.
In summary, a high percentage of HD
patients who have abnormal values of
liver enzymes and are anti-HCV and se-
rum HCV-RNA negative present an oc-
cult HCV infection. Further studies in-
volving a larger number of patients with
amuch longer observation period are re-
quired to elucidate the natural history
and clinical implications of occult HCV
infection in HD patients.
CONCISE METHODS
Ten HD units from different Spanish regions
participated in the enrollment of patients un-
der stable substitutive HD therapy. All viro-
logic assays were performed in a single center.
The inclusion criteria were (1) documented
ALT levels 28 IU/L (normal limit for HD
patients)5–7 and/or abnormal -GTP levels
(43 IU/L) for 6 mo before entry into the
study; (2) Persistently negative serologic
markers of HIV (anti-HIV), hepatitis B virus
(surface antigen and DNA), and HCV (anti-
HCV and HCV-RNA); and (3) exclusion of
all other causes of liver diseases (e.g., autoim-
munity, toxic hepatitis, metabolic disorders).
The study was approved by the coordinating
center’s ethics committee and conducted ac-
cording to the Declaration of Helsinki. Inclu-
sion criteria were fulfilled by 109 hemodialy-
sis patients who gave their consent to
participate in the study. Serum and PBMC
samples were collected from all patients on
the study entry day. Anti-HCV (INNOTEST
HCV Ab IV, Innogenetics, Ghent, Belgium)
and HCV-RNA were tested again in all of
these serum samples, confirming that all pa-
tients included were negative for these HCV
serologic markers. ALT and -GTP levels
were also measured.
PBMC samples were isolated from fresh
heparinized venous blood by gradient cen-
trifugation. Cells were divided into two ali-
quots: One was stored at 20°C in RNA-
Later (Ambion, Austin, TX) until its use for
detection of genomic and antigenomic
HCV-RNA and for HCV genotyping by
strand-specific quantitative real-time PCR.
The other aliquot was processed for detec-
tion of both HCV-RNA strands by fluores-
cence in situ hybridization. PBMC from 10
healthy volunteers who had normal liver
function tests and were repeatedly HCV-
RNA negative in PBMC were used as nega-
tive controls.
Detection of Genomic and
Antigenomic HCV-RNA and HCV
Genotyping
Total RNAwas isolated from 250l of serum
with TRizol LS Reagent (Invitrogen, Carls-
bad, CA) and from PBMC using the SV Total
RNA Isolation System (Promega, Madison,
WI). After precipitation, RNA pellets were
dissolved in diethyl-pyrocarbonate–treated
water, and total amount of RNA isolated
from PBMC was determined by spectropho-
tometry. The total RNA extracted from se-
rum or 0.5 g of total RNA from PBMC was
used for the detection of the 5 noncoding
region of genomic and antigenomic HCV-
RNA by strand-specific quantitative real-
time PCR. Synthesis of the corresponding
cDNA was performed at high temperature
using the thermostable enzyme Tth (Applied
Biosystems, Foster City, CA) as described
previously.12 Real-time PCR using fluores-
cence resonance energy transfer probes was
run in a Light Cycler (Roche Molecular Bio-
chemicals, Indianapolis, IN) with 2 l of
cDNA in a final volume of 20 l, using the
LightCycler FastStart DNAMaster HybProbe
Kit (RocheMolecular Biochemicals). Primers
and conditions of this strand-specific real-
time PCR have been reported.13 The fluores-
cence resonance energy transfer probes used
were described by Bullock et al.14 These allow
discrimination between HCV genotypes 1, 2,
3, and 4 by melting-curve analysis. Quantifi-
cation of both HCV-RNA strands was per-
formed using two standard curves con-
structed with 10-fold dilutions of synthetic
genomic and antigenomic HCV-RNA (from
3.2  108 to 0.32 copies). Quantification as-
say linearity ranged from3.2 to 3.2 108 cop-
ies of genomic or antigenomicHCV-RNAper
reaction. This assay was capable of detecting
3.2 molecules of the correct strand while un-
specifically detecting 107 to 108 copies of the
incorrect strand.13
For ensuring the specificity of the results,
HCV-RNA detection was performed blindly
on different days by two different operators.
In addition to PBMC from the 10 healthy an-
ti-HCV negative patients, total RNA isolated
from HepG2 cells and blanks were used as
negative controls. All procedures were per-
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formed following the recommendations of
Kwok and Higuchi.15
Phylogenetic Analysis
For discarding cross-contamination among
positive samples, theHCV core regionwas am-
plified from total RNA isolated from PBMC of
six randomly selected patients by reverse tran-
scriptase–PCR as described previously.10 The
302-bp core PCRproductswere cloned into the
pCR II TOPO vector (Invitrogen), and a mini-
mumof four clones from each patient were au-
tomatically sequenced. Sequences were aligned
with core sequences corresponding to all HCV
genotypes retrieved from GenBank, using the
ClustalX1.81program.16Phylogenetic andmo-
lecular evolutionary analyses were conducted
usingMEGA 2.1.17 Genetic distances were esti-
mated using the Kimura 2 parameter method,
andSEof thedistanceswere computedbyboot-
strap method (1000 replicates). Phylogenetic
treewas constructedwith theNeighbor-Joining
method, and its statistical significance was
tested by bootstrapmethod (1000 replicates).
Detection of the Genomic and
Antigenomic HCV-RNA in PBMC by
Fluorescence In Situ Hybridization
Genomic HCV-RNA was detected using a
complementary RNA probe obtained by in
vitro transcription of the pC5NCR plasmid
(which contains the complete 5 noncoding
region of theHCVgenome) in the presence of
digoxigenin-11-UTP (Roche Molecular Bio-
chemicals). Detection of the antigenomic
HCV-RNA was done with a complementary
digoxigenin-labeled RNA probe spanning
390 nucleotides of the HCV core region, ob-
tained by in vitro transcription of the pCcore
plasmid. Hybridization conditions for the in
situ detection of both HCV-RNA strands
were as described previously.18
Statistical Analysis
Statistical analysis was conducted with SPSS
15.0 (SPSS, Chicago, IL). Continuous vari-
ables were expressed as means  SD except
where indicated. Means were compared with
the t test according to the homogeneity of
variances. Categorical variables were ex-
pressed as percentages and were compared
with the 2 test. Demographic and clinical
data of the patients (gender, age, antecedents
of blood transfusions, duration of hemodial-
ysis, duration of abnormal levels of liver en-
zymes, and ALT and -GTP levels) and the
presence or absence of occult HCV infection
were included in a binary logistic regression
analysis to identify independent factors that
were associated with mortality.
ACKNOWLEDGMENTS
This work was funded by the Instituto de Sa-
lud Carlos III (Spain), grant FIS 05/1918.
We thank Dr. Rafael Selgas for support to
the study and Francisco Rodriguez-Salvanes
for reviewing the statistical analysis.
DISCLOSURES
None.
REFERENCES
1. Miller RH, Purcell RH: Hepatitis C virus
shares amine acid sequence similarity with
pestiviruses and flaviviruses as well as mem-
bers of two plant virus supergroups. Proc
Natl Acad Sci U S A 87: 2057–2061, 1990
2. Clarke B: Molecular virology of hepatitis C
virus. J Gen Virol 78: 2397–2410, 1997
3. Fabrizi F, Lunghi G, Ganeshan SV, Martin P,
Messa P: Hepatitis C virus infection and the
dialysis patient. Semin Dial 20: 416–422,
2007
4. Barril G, Traver JA: Decrease in the hepatitis
C virus (HCV) prevalence in hemodialysis pa-
tients in Spain: Effect of time, initiating HCV
prevalence studies and adoption of isolation
measures. Antiviral Res 60: 129–134, 2003
5. Recommendations for preventing transmis-
sion of infections among chronic hemodial-
ysis patients. MMWR Recomm Rep 50:
1–43, 2001
6. Barril G, Gonza´lez Parra E, Alca´zar R, Arenas
D, Campistol JM, Caramelo C, Carrasco M,
Carren˜o V, Espinosa M, Garcı´a Valdecasas J,
Go´rriz JL, Lo´pez MD, Martı´n L, Ruiz P, Terruel
JL, Spanish Society of Nephrology: Guidelines
on hemodialysis-associated viral infections.
Nefrologia 24[Suppl 2]: 43–66, 2004
7. Espinosa M, Martin-Malo A, Alvarez de Lara
MA, Soriano S, Aljama P: High ALT levels
predict viremia in anti-HCV-positive HD pa-
tients if a modified normal range of ALT is
applied. Clin Nephrol 54: 151–156, 2000
8. Lopes EP, Gouveia EC, Albuquerque AC,
Sette LH, Mello LA, Moreira RC, Coelho
MR: Determination of the cut-off value of
serum alanine aminotransferase in patients
undergoing hemodialysis to identify bio-
chemical activity in patients with hepatitis
C viremia. J Clin Virol 35: 298 –302, 2006
9. Yasuda K, Okuda K, Endo N, Ishiwatari Y,
Ikeda R, Hayashi H, Yokozeki K, Kobayashi S,
Irie Y: Hypoaminotransferasemia in patients
undergoing long-term hemodialysis: Clinical
and biochemical appraisal. Gastroenterol-
ogy 109: 1295–1300, 1995
10. Castillo I, Pardo M, Bartolome´ J, Ortiz-
Movilla N, Rodrı´guez-In˜igo E, de Lucas S,
Salas C, Jime´nez-Heffernan JA, Pe´rez-
Mota A, Graus J, Lo´pez-Alcorocho JM,
Carren˜o V: Occult hepatitis C virus infec-
tion in patients in whom the etiology of
persistently abnormal results of liver-func-
tion tests is unknown. J Infect Dis 189:
7–14, 2004
11. Schneeberger PM, Keur I, van Loon AM,
Mortier D, de Coul KO, van Haperen AV,
Sanna R, van Der Heijden TG, van Den
Hoven H, van Hamersvelt HW, Quint W, van
Doorn LJ: The prevalence and incidence of
hepatitis C virus infections among dialysis
patients in the Netherlands: A nationwide
prospective study. J Infect Dis 182: 1291–
1299, 2000
12. Castillo I, Rodrı´guez-In˜igo E, Lo´pez-Alcoro-
cho JM, Pardo M, Bartolome´ J, Carren˜o V:
Hepatitis C virus replicates in the liver of
patients who have a sustained response to
antiviral treatment. Clin Infect Dis 43: 1277–
1283, 2006
13. Bartolome´ J, Lo´pez-Alcorocho, Castillo I,
Rodrı´guez-In˜igo E, Quiroga JA, Palacios R,
Carren˜o V: Ultracentrifugation of serum
samples allows detection of hepatitis C virus
RNA in patients with occult hepatitis C. J Vi-
rol 81: 7710–7715, 2007
14. Bullock GC, Bruns DE, Haverstick DM: Hep-
atitis C genotype determination by melting
curve analysis with a single set of fluores-
cence resonance energy transfer probes.
Clin Chem 48: 2147–2154, 2002
15. Kwok S, Higuchi R: Avoiding false positive
with PCR. Nature 339: 237–238, 1989
16. Thompson JD, Gibson TJ, Plewniak F, Jean-
mougin F, Higgins DG: The ClustalX win-
dows interface: Flexible strategies for multi-
ple sequence alignment aided by quality
analysis tools. Nucleic Acids Res 24: 4876–
4882, 1997
17. Kumar S, Tamura K, Jakobsen IB, Nei M:
MEGA2: Molecular evolutionary genetics
analysis software. Bioinformatics 17: 1244–
1245, 2001
18. Castillo I, Rodrı´guez-In˜igo E, Bartolome´ J,
de Lucas S, Ortı´z-Movilla N, Lo´pez-Alcoro-
cho JM, Pardo M, Carren˜o V: Hepatitis C
virus replicates in peripheral blood mononu-
clear cells of patients with occult HCV infec-
tion. Gut 54: 682–685, 2005
See related editorial, “Occult Hepatitis C Virus In-
fection in Hemodialysis,” on pages 2248–2250.
BRIEF COMMUNICATION www.jasn.org
2292 Journal of the American Society of Nephrology J Am Soc Nephrol 19: 2288–2292, 2008
